Recent Updates
Recently added Catalysts

standardized turmeric root extract

Phase 1

Cystic Fibrosis | Small molecule | Respiratory |Seer, Inc.|Last Updated: Dec 25, 2007

Success Probability
Subscribe to view
Market & Valuation
Subscribe to view
Trial Design
UNCONTROLLEDDMCBiomarker
Total Trials1
Total Enrollment11
FDA Designations
No designations recorded
Clinical trial landscape

standardized turmeric root extract · 1 trial · 1 indication

Phase 1 1
NCT00219882Safety Study of Orally Administered Curcuminoids in Adult Subjects With Cystic FibrosisCystic Fibrosis
COMPLETED11 Analytics
PHASE1COMPLETED
Safety Study of Orally Administered Curcuminoids in Adult Subjects With Cystic Fibrosis
Cystic Fibrosis
NCT0021988211
Unlock trial analytics
Study Endpoints
Primary Endpoints
Safety and tolerability of 14 days of treatment with orally administered curcuminoids as assessed by adverse events, laboratory parameters, and spirometry.
14 days
Secondary Endpoints
(1) Pharmacokinetics of repeated doses of orally administered curcuminoids. (2) Change in nasal potential difference (NPD) measurements. (3) Change in sweat chloride measurements.
14 days
Unlock Study Endpoints
Study Design & Arms
AllocationNON_RANDOMIZED
MaskingNONE
ModelSINGLE_GROUP
PurposeTREATMENT
Treatment Arms
ArmTypeDescription
1EXPERIMENTALstandardized turmeric root extract
Interventions
NameTypeDescription
standardized turmeric root extractDRUG1.5 gm of standardized tumeric root extract three times per day for seven consecutive days, followed by 3 gm of standardized tumeric root extract three times per day for seven consecutive days
Unlock Study Design Details
Eligibility Criteria
Age Range18 Years to 40 Years
SexALL
Healthy VolunteersNo
Study Sites2

Inclusion Criteria: * Male or female 18 - 40 years of age. * Documented history of being homozygous for ΔF508 CFTR genotype. * Able to perform spirometry maneuvers, and have a forced expiratory volume at 1 second (FEV1) greater than or equal to 30% of predicted normal for age, gender, and height (K...

Countries:United States
Unlock Eligibility Criteria
Competitive Landscape -Cystic Fibrosis 18 trials
CompanyTickerTrialsLead PhaseDrugs
Vertex Pharmaceuticals IncorporatedVRTX9PHASE3VX-121/TEZ/D-IVA
Sionna Therapeutics, Inc.SION2PHASE2SION-719
BiomX Inc.PHGE1PHASE2BX004
Arcturus Therapeutics Holdings, Inc.ARCT1PHASE2ARCT-032
4D Molecular Therapeutics, Inc.FDMT1PHASE24D-710
Krystal Biotech, Inc.KRYS1PHASE1KB407
Illumina, Inc.ILMN1 - Undisclosed
Unlock Competitive Intelligence